CAR-T Meeting 2022 | Emerging CD19-targeted CAR-T treatment approaches for NHLs
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, comments on recent developments in CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapies in non-Hodgkin lymphomas (NHL). Prof. Jäger talks on bispecific CAR-Ts targeting both CD19 and CD20, allogeneic CAR-Ts (alloCAR-Ts), and combining CAR-Ts with bispecific antibodies. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Transcript (edited for clarity)
I think there are several areas to keep in mind. I think one, of course, is broaden the spectrum of indications within the CD19 CARs, and that’s currently happening. There are some areas where we are waiting for routine tools, CLL for instance. CNS lymphomas, I think is certainly an area which is quite interesting, and all other kinds of indolent and aggressive lymphomas with the CD19 CARs...
I think there are several areas to keep in mind. I think one, of course, is broaden the spectrum of indications within the CD19 CARs, and that’s currently happening. There are some areas where we are waiting for routine tools, CLL for instance. CNS lymphomas, I think is certainly an area which is quite interesting, and all other kinds of indolent and aggressive lymphomas with the CD19 CARs. What’s coming up is a number of bispecific CAR approaches, or dual CAR approaches where not only CD19 is targeted, but also CD20 simultaneously. There is, of course, also the possibility of combining CARs with bispecific antibodies, and I saw some really interesting data in the alloCAR field, which I think is now picking up and will probably show us some very interesting data at the next ASH meeting in a year or so.
Read more...
